• What is tumor profiling and how can it help me?

    by  • March 19, 2015

    Tumor profiling has become the mainstay of personalized oncology. It is already quite evident that key biological principles are shared between the tumors despite difference in their site and tissue of origin. Activated oncogene HER2 is a great example: once mutated or multiplied, this cancer gene becomes an engine to drive cancer cell growth...

    Read more →

    Meet Michelle Savage, Fox Chase’s New Genetic Counselor

    by  • February 10, 2015

    Michelle Savage was born and raised in Bucks County, PA and grew up familiar with Fox Chase Cancer Center. She completed her undergraduate studies at Boston University, earning her BA in biology, with a concentration in cell biology, molecular biology and genetics. She studied genetic counseling at Arcadia University in Glenside, PA and completed...

    Read more →

    Testicular cancer often affects young men

    by  • February 7, 2015

    Andrew Steinmetz works in retail and has outgoing personality. “I really like the pace of working in the store,” says Andrew Steinmetz, 23, who is a manager at a business supply store in Philadelphia. “Andrew’s upbeat and positive attitude is evident as he shares the story of his battle of testicular cancer. In January,...

    Read more →

    A New Procedure Called HIPEC Offers New Treatment Options for Cancer Patients

    by  • January 23, 2015

    The acronym HIPEC stands for hyperthermic intraperitoneal chemotherapy.  This procedure is a novel method of delivering chemotherapy in the operating room during surgery for the treatment of advanced cancers that have spread to the lining of the abdominal (peritoneal) cavity. The term hyperthermic refers to the increased temperature we use to make the tumor...

    Read more →

    Exciting News in the Fight Against Lung Cancer

    by  • January 17, 2015

    A news story in USA Today’s January 13, 2015 edition reported that a new cancer drug, Opdivo, is working so successfully that maker Bristol-Myers Squibb announced this week that it is ending a trial in lung cancer two years ahead of schedule. “We participated in this trial,” said Hossein Borghaei, DO, Chief, Thoracic Medical...

    Read more →